Apo-Dipyridamole , Persantine
Classifications: antiplatelet agent; platelet aggregate inhibitor; coronary vasodilator; Therapeutic: platelet aggregate inhibitor; coronary vasodilator
Pregnancy Category: B
25 mg, 50 mg, 75 mg tablets; 10 mg injection
Nonnitrate coronary vasodilator that increases coronary blood flow by selectively dilating coronary arteries, thereby increasing
myocardial oxygen supply. Additionally, it exhibits mild inotropic action as well as antiplatelet aggregation activity.
Has antiplatelet, and coronary vasodilator effects.
To prevent postoperative thromboembolic complications associated with prosthetic heart valves and as adjunct for thallium
To reduce rate of reinfarction following MI; to prevent TIAs (transient ischemic attacks) and coronary bypass graft occlusion.
Safety and efficacy in children <12 y are not established.
Hypotension, anticoagulant therapy; aspirin sensitivity; elderly; severe hepatic dysfunction; syncopey; pregnancy (category
Route & Dosage
|Prevention of Thromboembolism in Cardiac Valve Replacement
Adult: PO 75100 mg q.i.d.
Child: PO 12 mg t.i.d.
Adult: PO 150400 mg/d in divided doses
Thallium Stress Test
Adult: IV 0.142 mg/kg/min for 4 min
- Give on an empty stomach at least 1 h before or 2 h after meals, with a full glass of water. Physician may prescribe with
food if gastric distress persists.
PREPARE: Direct: Dilute to at least a 1:2 ratio with 0.45% NaCl, NS, or D5W to yield a final volume of 2050 mL.
ADMINISTER: Direct: Give a single dose over 4 min (0.142 mg/kg/min).
- Store in tightly closed container at 15°30° C (59°86° F) unless otherwise directed. Protect
injection from direct light.
Adverse Effects (≥1%)
Usually dose related, minimal, and transient. CNS:
Headache, dizziness, faintness, syncope, weakness. CV:
Peripheral vasodilation, flushing. GI:
Nausea, vomiting, diarrhea, abdominal distress. Skin:
Skin rash, pruritus.
Readily absorbed from GI tract. Peak:
45150 min. Distribution:
Small amount crosses placenta. Metabolism:
In liver. Elimination:
Mainly in feces. Half-Life:
Assessment & Drug Effects
- Monitor therapeutic effectiveness. Clinical response may not be evident before second or third month of continuous therapy.
Effects include reduced frequency or elimination of anginal episodes, improved exercise tolerance, reduced requirement for
Patient & Family Education
- Notify physician of any adverse effects.
- Make all position changes slowly and in stages, especially from recumbent to upright posture, if postural hypotension or
dizziness is a problem.